Telemedicine and virtual healthcare company, Teladoc Health (NYSE: TDOC) gained in pre-market trading at the time of writing on Wednesday as the company’s losses narrowed in Q2 to $0.40 per share from a loss of $19.22 per share in the same period last year as compared to Street estimates of a loss of $0.41 per share.
The company’s revenues surged 10% year-over-year to $652.4 million, beating consensus estimates of $649.2 million.
Looking forward, the management has now projected FY23 losses between $1.60 and $1.25 per share as compared to Street estimates of a loss of $1.34 per share. Revenues are expected to be in the range of $2.6 billion to $2.675 billion versus consensus estimates of $2.62 billion.
In the third quarter, TDOC has forecasted revenues between $650 million and $675 million while net loss is anticipated to range from $0.50 to $0.40 per share.
Analysts are cautiously optimistic about TDOC stock with a Moderate Buy consensus rating based on six Buys and 10 Holds.
